CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Key facts

Sponsor

Beijing Tongren Hospital

Intervention

CD19/CD22-bispecific CAR-T cells(drug)

Enrollment

100 enrolled

Eligibility

14-85 years · All sexes

Timeline

2022 – 2026

Study locations (1)

• Liang Wang, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07069699
  Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
  National Cancer Institute (NCI)
• RECRUITINGEARLY PHASE1NCT07429461
  Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
  Zhejiang University
• RECRUITINGEARLY PHASE1NCT06793241
  Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
  Zhejiang University
• RECRUITINGPHASE2, PHASE3NCT06764238
  Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGNCT06796517
  Immunotherapy in Lymphoma
  Sung-Soo Park
• RECRUITINGPHASE1NCT06060782
  Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
  Fifth Affiliated Hospital, Sun Yat-Sen University
• RECRUITINGPHASE2NCT06179524
  CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
  Beijing Yongtai Ruike Biotechnology Company Ltd
• RECRUITINGPHASE1NCT06056752
  QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
  Anhui Provincial Hospital

See all trials for Burkitt lymphoma →